Sufentanil attenuates oxaliplatin cytotoxicity via inhibiting connexin 43‑composed gap junction function

Zhang,Qi; Su,Min

doi:10.3892/mmr.2017.6669

Sufentanil attenuates oxaliplatin cytotoxicity via inhibiting connexin 43‑composed gap junction function

Authors:
- Qi Zhang
- Min Su
View Affiliations

Affiliations: Department of Oncology, Hospital Affiliated to Hubei University of Arts and Science/Xiangyang Central Hospital, Xiangyang, Hubei 441021, P.R. China
Published online on: May 31, 2017 https://doi.org/10.3892/mmr.2017.6669
Pages: 943-948

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Comprehensive strategies for the treatment of colorectal cancer (CRC) have become increasingly important. One of the most important factors is pain relief. Therefore, patients with CRC are concurrently treated with analgesics and chemotherapeutic agents; however, the effects of analgesics on the therapeutic activity of chemotherapeutic agents remain largely unknown. The present study investigated the effects of three widely used analgesics in clinics: Fentanyl, remifentanil and sufentanil, on the cytotoxicity of oxaliplatin, a commonly used chemotherapeutic agent for CRC. Furthermore, the underlying mechanisms of those effects in association with connexin 43 (Cx43)‑composed gap junction (GJ) function were analyzed. The Lovo, Colo320, HCT116 and HT29 human CRC cell lines, with or without Cx43 expression, were used to examine the effects of the three analgesics on the cytotoxicity of oxaliplatin. The results demonstrated that in the cell lines expressing Cx43 (Lovo and Colo320), the cytotoxicity of oxaliplatin was attenuated and Cx43 GJ function was inhibited. Sufentanil, not fentanyl or remifentanil, inhibited Cx43 GJ function effectively, and reduced the cytotoxicity of oxaliplatin. In contrast, these effects were not observed in the other two colon cancer cell lines not expressing Cx43 (HCT116 and HT29). These results suggested that alternation of Cx43 GJ function may regulate the cytotoxicity of oxaliplatin in regard to CRC. Furthermore, sufentanil, not fentanyl or remifentanil, suppressed the cytotoxicity of oxaliplatin through inhibition of Cx43 GJ function. These results may be beneficial for the treatment of CRC and reduction of treatment resistance.

View Figures

View References

1	Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB and El-Rifai W: Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res. 68:10315–10323. 2008. View Article : Google Scholar : PubMed/NCBI
2	Hirschi B, Gallmeier E, Ziesch A, Marschall M and Kolligs FT: Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. Mol Cancer. 13:1222014. View Article : Google Scholar : PubMed/NCBI
3	Tan S, Peng X, Peng W, Zhao Y and Wei Y: Enhancement of oxaliplatin-induced cell apoptosis and tumor suppression by 3-methyladenine in colon cancer. Oncol Lett. 9:2056–2062. 2015.PubMed/NCBI
4	Choi JH, Won YW, Kim HS, Oh YH, Lim S and Kim HJ: Oxaliplatin-induced sinusoidal obstruction syndrome mimicking metastatic colon cancer in the liver. Oncol Lett. 11:2861–2864. 2016.PubMed/NCBI
5	Fan F, Gray MJ, Dallas NA, Yang AD, Van Buren G II, Camp ER and Ellis LM: Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. Mol Cancer Ther. 7:3064–3070. 2008. View Article : Google Scholar : PubMed/NCBI
6	Wang Q, You T, Yuan D, Han X, Hong X, He B, Wang L, Tong X, Tao L and Harris AL: Cisplatin and oxaliplatin inhibit gap junctional communication by direct action and by reduction of connexin expression, thereby counteracting cytotoxic efficacy. J Pharmacol Exp Ther. 333:903–911. 2010. View Article : Google Scholar : PubMed/NCBI
7	Luo C, Yuan D, Li X, Yao W, Luo G, Chi X, Li H, Irwin MG, Xia Z and Hei Z: Propofol attenuated acute kidney injury after orthotopic liver transplantation via inhibiting gap junction composed of connexin 32. Anesthesiology. 122:72–86. 2015. View Article : Google Scholar : PubMed/NCBI
8	Graziano AC, Parenti R, Avola R and Cardile V: Krabbe disease: Involvement of connexin43 in the apoptotic effects of sphingolipid psychosine on mouse oligodendrocyte precursors. Apoptosis. 21:25–35. 2016. View Article : Google Scholar : PubMed/NCBI
9	Spagnol G, Kieken F, Kopanic JL, Li H, Zach S, Stauch KL, Grosely R and Sorgen PL: Structural studies of the Nedd4 WW domains and their selectivity for the connexin43 (Cx43) carboxyl terminus. J Biol Chem. 291:7637–7650. 2016. View Article : Google Scholar : PubMed/NCBI
10	Gielen PR, Aftab Q, Ma N, Chen VC, Hong X, Lozinsky S, Naus CC and Sin WC: Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. Neuropharmacology. 75:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
11	Le HT, Sin WC, Lozinsky S, Bechberger J, Vega JL, Guo XQ, Sáez JC and Naus CC: Gap junction intercellular communication mediated by connexin43 in astrocytes is essential for their resistance to oxidative stress. J Biol Chem. 289:1345–1354. 2014. View Article : Google Scholar : PubMed/NCBI
12	He B, Tong X, Wang L, Wang Q, Ye H, Liu B, Hong X, Tao L and Harris AL: Tramadol and flurbiprofen depress the cytotoxicity of cisplatin via their effects on gap junctions. Clin Cancer Res. 15:5803–5810. 2009. View Article : Google Scholar : PubMed/NCBI
13	Myers J and Shetty N: Going beyond efficacy: Strategies for cancer pain management. Curr Oncol. 15:(Suppl 1). S41–S49. 2008. View Article : Google Scholar : PubMed/NCBI
14	Sirnes S, Bruun J, Kolberg M, Kjenseth A, Lind GE, Svindland A, Brech A, Nesbakken A, Lothe RA, Leithe E and Rivedal E: Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. Int J Cancer. 131:570–581. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhao Y, Liu B, Wang Q, Yuan D, Yang Y, Hong X, Wang X and Tao L: Propofol depresses the cytotoxicity of X-ray irradiation through inhibition of gap junctions. Anesth Analg. 112:1088–1095. 2011. View Article : Google Scholar : PubMed/NCBI
16	Yuan DD, Chi XJ, Jin Y, Li X, Ge M, Gao WL, Guan JQ, Zhang AL and Hei ZQ: Intestinal injury following liver transplantation was mediated by TLR4/NF-κB activation-induced cell apoptosis. Mol Med Rep. 13:1525–1532. 2016.PubMed/NCBI
17	Yuan D, Sun G, Zhang R, Luo C, Ge M, Luo G and Hei Z: Connexin 43 expressed in endothelial cells modulates monocyte-endothelial adhesion by regulating cell adhesion proteins. Mol Med Rep. 12:7146–7152. 2015.PubMed/NCBI
18	Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66:683–691. 2017. View Article : Google Scholar : PubMed/NCBI
19	Alcindor T and Beauger N: Oxaliplatin: A review in the era of molecularly targeted therapy. Curr Oncol. 18:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
20	Howells LM, Sale S, Sriramareddy SN, Irving GR, Jones DJ, Ottley CJ, Pearson DG, Mann CD, Manson MM, Berry DP, et al: Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int J Cancer. 129:476–486. 2011. View Article : Google Scholar : PubMed/NCBI
21	Ekblad L, Kjellström J and Johnsson A: Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Anticancer Drugs. 21:523–531. 2010. View Article : Google Scholar : PubMed/NCBI
22	Chen J, Huang XF, Qiao L and Katsifis A: Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol. 2:27–33. 2011.PubMed/NCBI
23	Peng L, Zhu H, Wang J, Sui H, Zhang H, Jin C, Li L, Xu T and Miao R: MiR-492 is functionally involved in Oxaliplatin resistance in colon cancer cells LS174T via its regulating the expression of CD147. Mol Cell Biochem. 405:73–79. 2015. View Article : Google Scholar : PubMed/NCBI
24	To KK, Poon DC, Wei Y, Wang F, Lin G and Fu LW: Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer. Data Brief. 7:437–444. 2016. View Article : Google Scholar : PubMed/NCBI
25	Segretain D, Decrouy X, Dompierre J, Escalier D, Rahman N, Fiorini C, Mograbi B, Siffroi JP, Huhtaniemi I, Fenichel P and Pointis G: Sequestration of connexin43 in the early endosomes: An early event of Leydig cell tumor progression. Mol Carcinog. 38:179–187. 2003. View Article : Google Scholar : PubMed/NCBI
26	Leithe E, Sirnes S, Omori Y and Rivedal E: Downregulation of gap junctions in cancer cells. Crit Rev Oncog. 12:225–256. 2006. View Article : Google Scholar : PubMed/NCBI
27	Sanson M, Marcaud V, Robin E, Valery C, Sturtz F and Zalc B: Connexin 43-mediated bystander effect in two rat glioma cell models. Cancer Gene Ther. 9:149–155. 2002. View Article : Google Scholar : PubMed/NCBI
28	Fossepre M, Leherte L, Laaksonen A and Vercauteren DP: On the modularity of the intrinsic flexibility of the µ opioid receptor: A computational study. PloS One. 9:e1158562014. View Article : Google Scholar : PubMed/NCBI
29	Katritch V, Cherezov V and Stevens RC: Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol. 53:531–556. 2013. View Article : Google Scholar : PubMed/NCBI
30	Wu W, Wei N, Jiang CN, Cui S and Yuan J: Effects of sufentanil on human gastric cancer cell line SGC-7901 in vitro. Cent Eur J Immunol. 39:299–305. 2014. View Article : Google Scholar : PubMed/NCBI